Enzolytics Inc. (ENZC) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $2.42M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerEnzolytics Inc. (ENZC) trades at $0.0005. Enzolytics, Inc. is a biotechnology company focused on developing and commercializing proprietary proteins for treating infectious diseases, particularly HIV. Market cap: $2.42M, Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for ENZC: ENZC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Enzolytics Inc. (ENZC) Healthcare & Pipeline Overview
Enzolytics, Inc. is a drug development company specializing in proprietary proteins and monoclonal antibodies for treating infectious diseases like HIV. With clinically tested anti-HIV therapeutics and a proprietary cell line, Enzolytics aims to provide non-toxic passive immunotherapy solutions within the competitive biotechnology sector.
What Is the Investment Thesis for ENZC?
Enzolytics, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on developing proprietary proteins and monoclonal antibodies for HIV treatment offers potential for significant growth if clinical trials are successful and regulatory approvals are obtained. Key value drivers include the successful commercialization of its anti-HIV therapeutics and the expansion of its proprietary cell line technology. However, the company faces significant challenges, including limited financial resources, competition from established pharmaceutical companies, and the inherent risks associated with drug development and regulatory approval processes. The company's negative P/E ratio of -2.98 and OTC market listing highlight the speculative nature of this investment.
Based on FMP financials and quantitative analysis
ENZC Key Highlights
Enzolytics focuses on developing proprietary proteins for the treatment of debilitating infectious diseases.
- The company possesses patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies.
- Enzolytics has clinically tested anti-HIV therapeutics, indicating progress towards potential commercialization.
- The company has created a proprietary cell line that produces human monoclonal antibodies that target and neutralize the HIV virus.
- Enzolytics operates with a small team of 1 employee, reflecting its early-stage development.
Who Are ENZC's Competitors?
ENZC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BMNDF Biomind Labs Inc. | $0.25 | 0.00% | $19.4M | — |
| CAIHF Chia Tai Enterprises International Limited | $1.07 | 0.00% | $270M | — |
| RLYB Rallybio Corporation | $16.65 | +0.06% | $88.5M | — |
| ICCC ImmuCell Corporation | $10.24 | -0.10% | $93.6M | — |
| ORMP Oramed Pharmaceuticals Inc. | $4.08 | -1.21% | $170M | — |
| NAGE Niagen Bioscience Inc | $2.44 | +0.41% | $190M | — |
| QTTB Q32 Bio Inc. | $8.45 | -2.31% | $252M | — |
| CLYM Climb Bio, Inc. | $8.81 | -13.54% | $506M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ENZC's Key Strengths?
Proprietary technology for producing monoclonal antibodies.
- Clinically tested anti-HIV therapeutics.
- Focus on non-toxic passive immunotherapy.
- Potential for significant revenue growth if therapeutics are commercialized.
What Are ENZC's Weaknesses?
Limited financial resources.
- Small team and limited infrastructure.
- Dependence on the success of its anti-HIV therapeutics.
- OTC market listing indicates higher risk.
What Are the Key Risks for ENZC?
Financial-distress signal — its Altman Z-Score of -1.76 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals for therapeutics.
- Competition from established pharmaceutical companies.
- Patent expiration and the emergence of biosimilars.
- Limited financial resources and dependence on external funding.
- OTC market listing indicates higher risk and potential for volatility.
What Threats Does ENZC Face?
- Competition from established pharmaceutical companies.
- Regulatory hurdles and the risk of clinical trial failures.
- Patent expiration and the emergence of biosimilars.
- Economic downturns and changes in healthcare policy.
What Are ENZC's Competitive Advantages?
- Patented anti-HIV therapeutics provide intellectual property protection.
- Proprietary methodology for producing human IgG1 monoclonal antibodies offers a competitive advantage.
- Clinically tested therapeutics demonstrate progress towards commercialization.
- Proprietary cell line for producing human monoclonal antibodies creates a barrier to entry.
What Does ENZC Do?
Enzolytics, Inc., headquartered in Plano, Texas, is a biotechnology company dedicated to the development and commercialization of innovative protein-based therapeutics for debilitating infectious diseases. The company's primary focus is on creating treatments for HIV, leveraging its patented anti-HIV therapeutics and a unique methodology for producing human IgG1 monoclonal antibodies. These antibodies are designed to target and neutralize the HIV virus through non-toxic passive immunotherapy. Enzolytics has developed a proprietary cell line capable of producing human monoclonal antibodies, representing a significant advancement in its therapeutic approach. The company has already conducted clinical testing of its anti-HIV therapeutics, demonstrating a commitment to advancing its research and development efforts towards commercialization. Enzolytics' approach centers around providing innovative solutions for infectious diseases, marking it as a player in the biotechnology space.
What Products and Services Does ENZC Offer?
- Develop proprietary proteins for treating infectious diseases.
- Focus on commercializing anti-HIV therapeutics.
- Utilize a patented methodology for producing human IgG1 monoclonal antibodies.
- Target infectious diseases with non-toxic passive immunotherapy.
- Conduct clinical testing of anti-HIV therapeutics.
- Create a proprietary cell line that produces human monoclonal antibodies.
- Target and neutralize the HIV virus with monoclonal antibodies.
How Does ENZC Make Money?
- Develop and patent proprietary protein-based therapeutics.
- License or sell therapeutics to pharmaceutical companies or healthcare providers.
- Generate revenue through research grants and collaborations.
- Potentially manufacture and distribute therapeutics directly.
What Industry Does ENZC Operate In?
Enzolytics, Inc. operates within the competitive biotechnology industry, which is characterized by rapid innovation, high research and development costs, and stringent regulatory requirements. The market for HIV therapeutics is well-established but continues to evolve with the emergence of new treatment approaches and drug resistance. Enzolytics' focus on monoclonal antibodies and passive immunotherapy positions it within a growing segment of the market, but it faces competition from larger pharmaceutical companies with greater resources and established market presence. The company's success will depend on its ability to demonstrate the safety and efficacy of its therapeutics and secure regulatory approvals in a timely manner.
Who Are ENZC's Key Customers?
- Patients suffering from HIV and other infectious diseases.
- Pharmaceutical companies seeking novel therapeutics.
- Healthcare providers treating infectious diseases.
- Research institutions conducting infectious disease research.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Enzolytics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Plano, US. The company is led by CEO Steven Sharabura. ENZC has traded publicly since 2009.
Enzolytics Inc. (ENZC) Valuation Context
Valued at $2.42M, ENZC is classified as a micro-cap stock.
Key Financial Metrics
Return on equity for Enzolytics Inc. stands at 0.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.1%, showing how much profit it generates from its asset base. A current ratio of 0.63 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -5.4%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Enzolytics Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.76 places it in the distress zone, a signal of elevated financial risk.
ENZC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
ENZC Latest News
No recent news available for ENZC.
ENZC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ENZC.
Price Targets
Wall Street price target analysis for ENZC.
ENZC MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ENZC; grades run from A+ (80-100) to F (below 30).
Leadership: Steven Sharabura
CEO
Steven Sharabura is the CEO of Enzolytics Inc. His background includes managing the company's operations and strategic direction. As CEO, he is responsible for overseeing the development and commercialization of Enzolytics' proprietary therapeutics.
Track Record: Under Steven Sharabura's leadership, Enzolytics has focused on advancing its anti-HIV therapeutics and developing its proprietary cell line technology. Key milestones include the clinical testing of anti-HIV therapeutics. However, specific details regarding his track record and achievements are not available in the provided data.
ENZC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Enzolytics may not meet the minimum financial or reporting requirements of the higher tiers, such as OTCQX or OTCQB. Companies in this tier may have limited financial disclosures and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Low trading volume and liquidity can lead to price volatility.
- Higher potential for fraud or manipulation compared to listed stocks.
- OTC Other status indicates the company may not meet minimum financial standards.
- Potential for delisting or trading suspensions.
- Verify the company's registration and regulatory filings.
- Review the company's financial statements, if available.
- Assess the company's management team and their experience.
- Research the company's products and market potential.
- Evaluate the company's competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Patented anti-HIV therapeutics suggest intellectual property protection.
- Clinical testing of therapeutics indicates progress towards commercialization.
- Focus on developing innovative solutions for infectious diseases.
- Company has been in operation for several years.
- Company headquarters are located in Plano, Texas.
Common Questions About ENZC (Healthcare)
What do analysts say about ENZC stock?
As of 2026-03-16, there is no available analyst coverage or consensus on Enzolytics Inc. (ENZC) stock. This is likely due to the company's small market capitalization, OTC listing, and early stage of development.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on limited data available.
- OTC market stocks carry higher risk.